ArriVent BioPharma (NASDAQ:AVBP) Given New $36.00 Price Target at HC Wainwright

ArriVent BioPharma (NASDAQ:AVBP) had its target price hoisted by HC Wainwright from $30.00 to $36.00 in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and issued a $35.00 price target on shares of ArriVent BioPharma in a research note on Thursday, August 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, ArriVent BioPharma presently has an average rating of Buy and a consensus target price of $36.80.

ArriVent BioPharma Stock Down 6.2 %

AVBP opened at $23.79 on Tuesday. The stock’s 50 day moving average price is $22.81 and its two-hundred day moving average price is $19.82. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $30.99.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65). On average, sell-side analysts anticipate that ArriVent BioPharma will post -3.03 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in ArriVent BioPharma in the first quarter valued at about $83,000. American International Group Inc. acquired a new position in ArriVent BioPharma in the first quarter valued at about $87,000. Rhumbline Advisers grew its stake in ArriVent BioPharma by 30.1% in the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock valued at $236,000 after acquiring an additional 2,942 shares during the period. Blackstone Inc. acquired a new position in shares of ArriVent BioPharma during the first quarter worth about $446,000. Finally, Bank of New York Mellon Corp boosted its position in shares of ArriVent BioPharma by 31.4% during the second quarter. Bank of New York Mellon Corp now owns 29,847 shares of the company’s stock worth $554,000 after buying an additional 7,140 shares during the period. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.